• inhibits platelet aggregation 
• indicated for preventing adverse thromboembolic phenomena in patients with unstable angina or non-Q-wave myocardial infarction and those undergoing percutaneous coronary intervention 
• intended for use with heparin and aspirin  

• 180 ug/kg as soon as possible following diagnosis; given IV push over 1-2 minutes 
• follow immediately with continuous infusion 

• infuse at 2 ug/kg/min 
• administer undiluted from vial 
• continue infusion until discharge, initiation of coronary artery bypass grafting surgery or at discretion of physician for up to 72 hours; discontinue 4 hours prior to surgery 
• if patient undergoes PTCA, infusion should be continued for up to 20-24 hours post procedure, for a total of 90-96 hours 

 

Patient Weight (kg)	Bolus Volume in ml (2 mg/ml)	Infusion Rate in ml/h (0.75mg/ml)
37-41	3.4	6
42-46	4	7
47-53	4.5	8
54-59	5	9
60-65	5.6	10
66-71	6.2	11
72-78	6.8	12
79-84	7.3	13
85-90	7.9	14
91-96	8.5	15
97-103	9	16
104-109	9.5	17
110-115	10.2	18
116-121	10.7	19
>121	11.3	20

• in patients with history of bleeding diathesis or evidence of active abnormal bleeding within the previous 30 days 
• severe hypertension (SBP>200 or DBP>110) not adequately controlled on antihypertensive therapy 
• major surgery within the preceding 6 weeks 
• history of stroke within 30 days or any history of hemorrhagic stroke 
• platelet count < 100 
• serum creatinine >165 or dependence on hemodialysis 
• clinically significant liver disease 

• bleeding 
• thrombocytopenia 

• should be used cautiously with other medications that affect hemostasis, including oral anticoagulants, non-steroidal antiinflammatories, dipyridamole, ticlopidine and clopidogrel 

INR/PTT 

platelet count; hemoglobin 

bleeding 

ECG 

• Must be administered by a physician. 
• Should not be infused through the injection port of the right heart catheter. 
• Must be administered as a continuous infusion via an infusion pump.